317 related articles for article (PubMed ID: 33066143)
61. Synthesis of desaza analogues of annomontine and canthin-4-one alkaloids.
Strödke B; Gehring AP; Bracher F
Arch Pharm (Weinheim); 2015 Feb; 348(2):125-31. PubMed ID: 25664630
[TBL] [Abstract][Full Text] [Related]
62. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
63. The role of Plk3 in oncogenesis.
Helmke C; Becker S; Strebhardt K
Oncogene; 2016 Jan; 35(2):135-47. PubMed ID: 25915845
[TBL] [Abstract][Full Text] [Related]
64. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
65. Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations.
Couñago RM; Allerston CK; Savitsky P; Azevedo H; Godoi PH; Wells CI; Mascarello A; de Souza Gama FH; Massirer KB; Zuercher WJ; Guimarães CRW; Gileadi O
Sci Rep; 2017 Aug; 7(1):7501. PubMed ID: 28790404
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
Szymiczek A; Carbone M; Pastorino S; Napolitano A; Tanji M; Minaai M; Pagano I; Mason JM; Pass HI; Bray MR; Mak TW; Yang H
Oncogene; 2017 Nov; 36(46):6501-6507. PubMed ID: 28759042
[TBL] [Abstract][Full Text] [Related]
67. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
68. ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents.
Cozza G; Bortolato A; Menta E; Cavalletti E; Spinelli S; Moro S
Anticancer Agents Med Chem; 2009 Sep; 9(7):778-86. PubMed ID: 19799530
[TBL] [Abstract][Full Text] [Related]
69. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
70. Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization.
Mohanty S; Oruganty K; Kwon A; Byrne DP; Ferries S; Ruan Z; Hanold LE; Katiyar S; Kennedy EJ; Eyers PA; Kannan N
PLoS Genet; 2016 Feb; 12(2):e1005885. PubMed ID: 26925779
[TBL] [Abstract][Full Text] [Related]
71. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
[TBL] [Abstract][Full Text] [Related]
72. Molecular targets for the treatment of testicular germ cell tumors.
Chieffi P
Mini Rev Med Chem; 2007 Jul; 7(7):755-9. PubMed ID: 17627586
[TBL] [Abstract][Full Text] [Related]
73. Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
Rothweiler U; Stensen W; Brandsdal BO; Isaksson J; Leeson FA; Engh RA; Svendsen JS
J Med Chem; 2016 Nov; 59(21):9814-9824. PubMed ID: 27736065
[TBL] [Abstract][Full Text] [Related]
74. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
75. Two nucleus-localized CDK-like kinases with crucial roles for malaria parasite erythrocytic replication are involved in phosphorylation of splicing factor.
Agarwal S; Kern S; Halbert J; Przyborski JM; Baumeister S; Dandekar T; Doerig C; Pradel G
J Cell Biochem; 2011 May; 112(5):1295-310. PubMed ID: 21312235
[TBL] [Abstract][Full Text] [Related]
76. TNK2 as a key drug target for the treatment of metastatic colorectal cancer.
Qi L; Ding Y
Int J Biol Macromol; 2018 Nov; 119():48-52. PubMed ID: 30036625
[TBL] [Abstract][Full Text] [Related]
77. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
78. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
79. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
80. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
